NR1H4 and metabolic dysfunction-associated steatohepatitis: Obeticholic acid (OCA, INT-747) is a bile acid-derived FXR agonist currently in phase III trials for the treatment of NASH and has already shown its potential for treating hepatic steatosis, inflammation, and fibrosis while increasing insulin sensitivity9–11.